Media headlines about Enzo Biochem (NYSE:ENZ) have been trending somewhat positive recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Enzo Biochem earned a media sentiment score of 0.09 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 47.6632103013134 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- What Will Happen to Enzo Biochem, Inc. (ENZ) Next? The Stock Just Reaches 1 Year Low – NMSU H?r?ld (nmsuherald.com)
- Head-To-Head Comparison: Enzo Biochem (ENZ) versus Its Competitors (americanbankingnews.com)
- Edited Transcript of ENZ earnings conference call or presentation 13-Mar-18 12:30pm GMT (finance.yahoo.com)
- Enzo Biochem, Inc. (ENZ) price is down -33.57% off its 200-SMA – The Stocks News (press release) (thestocksnews.com)
Separately, ValuEngine downgraded Enzo Biochem from a “hold” rating to a “sell” rating in a report on Thursday, March 1st.
Enzo Biochem (NYSE:ENZ) last released its quarterly earnings data on Monday, March 12th. The medical research company reported ($0.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.03). Enzo Biochem had a negative return on equity of 2.95% and a negative net margin of 1.38%. The firm had revenue of $26.95 million during the quarter, compared to analyst estimates of $27.35 million.
In related news, CEO Elazar Rabbani sold 14,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the transaction, the chief executive officer now owns 1,867,202 shares in the company, valued at $14,470,815.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Barry W. Weiner sold 11,000 shares of the stock in a transaction that occurred on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the transaction, the chief financial officer now owns 1,313,111 shares in the company, valued at approximately $10,176,610.25. The disclosure for this sale can be found here. Corporate insiders own 8.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Enzo Biochem (ENZ) Earns Media Impact Rating of 0.09” was first posted by Ticker Report and is the property of of Ticker Report. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of United States and international trademark & copyright law. The legal version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3296765/enzo-biochem-enz-earns-media-impact-rating-of-0-09.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.